Tyra Biosciences, Inc. · NASDAQ:TYRA
Tyra Biosciences — Investor Presentation (September 2026)
47 slides from Tyra Biosciences's investor presentation, September 2026
Slide 1: Corporate Deck
Corporate Deck September 2026
Slide 2: Disclaimers
Disclaimers FORWARD-LOOKING STATEMENTS AND MARKET DATA We caution you that this presentation contains forward-looking statements. efficacy observed to date may not continue in ongoing or future studies; than we expect; unstable market and economic conditions, geopolitical All statements other than s
Slide 3: Gearing up for potential pivotal trials in 3 blockbuster indications
Gearing up for potential pivotal trials in 3 blockbuster indications Validated NASDAQ: FGFR3 alterations drive conditions with high unmet needs Target TYRA CASH: The first oral, once-daily, highly selective FGFR3 inhibitor Differentiated $727M (Pro-forma 2Q26)* 60mg PoC Molecule IR NMIBC All MLs: 79
Slide 4: Our expertise in FGFR biology creates a differentiated pipeline
Our expertise in FGFR biology creates a differentiated pipeline Estimated Annual US IND- Phase Dabogratinib Target Addressable1 Discovery Enabling 1 2 3 LG UTUC FGFR3 ~3K IR NMIBC FGFR3 ~35K ACH FGFR3 ~3K Other TYRA-430 HCC FGF19 ~15K TYRA-200 ICC FGFR1–3 ~6K CHEMISTRY LG UTUC: Low Grade Upper Tract
Slide 5: TYRA's highly selective FGFR3 inhibitor: Our development paths in Urology and ACH
TYRA’s highly selective FGFR3 inhibitor Our development paths in Urology and ACH 5
Slide 6: FGFR3 drives unmet need in multiple large market opportunities
FGFR3 drives unmet need in multiple large market opportunities Dabogratinib Has the potential to address these indications TOTAL UROTHELIAL TOTAL FGFR3-RELATED CARCINOMA (UC) SKELETAL DYSPLASIA ~45% FGFR3 | ~80,000/yr (US) >40,000/yr (US) INTERMEDIATE RISK NMIBC ~70% FGFR3 | ~35,000/yr (US) ACHONDRO
Slide 7: Our SNAP platform was able to address an intractable problem
Our SNAP platform was able to address an intractable problem FGFR isoform selectivity Subtle, but distinct differences at key interaction zones along the pocket walls Dabogratinib dozens of high-resolution FGFR3 specific crystal structures inhibitor FGFR1 FGFR3 FGFR1 FGFR3 MOLECULAR MODEL CRYSTALLOG
Slide 8: Dabogratinib is a potential first-in-class, selective FGFR3 inhibitor
Dabogratinib is a potential first-in-class, selective FGFR3 inhibitor Selectivity observed for dabogratinib vs. approved/late-stage clinical compounds: in vitro Ba/F3 Cellular IC50 (nM) E erdafitinib F futibatinib P pemigatinib I infigratinib D dabogratinib 63x FGFR1 FE P I 19x D FGFR2 FE P I D FGFR
Slide 9: TYRA's highly selective FGFR3 inhibitor: Our development paths in Urology and ACH
TYRA’s highly selective FGFR3 inhibitor Our development paths in Urology and ACH 9
Slide 10: High FGFR3+ rate drives an outsized opportunity in IR NMIBC
High FGFR3+ rate drives an outsized opportunity in IR NMIBC Total seeking Percentage treatment each year FGFR3+ FGFR3+ seeking new treatment 0 20 40 60 80 ALL BLADDER 820K+ people living with bladder cancer and UTUC in the US ~185K ~45% ~80K LG UTUC No patient-friendly oral Tx ~3.5K ~85% ~3.0K to re
Slide 11: IR NMIBC
IR NMIBC 11
Slide 12: Most LG IR NMIBC patients don't receive Tx to prevent recurrence
Most LG IR NMIBC patients don’t receive Tx to prevent recurrence ~70% forego …despite …and a high rate This may be why adjuvant Tx1…. efficacy2… of recurrence3 44% Recurrence 40 40 Progression ~70% Watch & Wait Recurrence 30 30 6–30 Risk Reduction 20 times 20 Patients Treated with Adjuvant IVe Chemo
Slide 13: FGFR3+ patients benefit from sustained FGFR3 inhibition
FGFR3+ patients benefit from sustained FGFR3 inhibition FGFR3+ VALIDATED TARGET IN IR NMIBC EVIDENCE SUSTAINED INHIBITION MAINTAINED RESPONSES Seek Treatment1 More Recurrent (per year) Median RFS2 (months) TAR-210 100% durability while on therapy Pan-FGFR Pretzel 3 of 4 evaluated recurred within 3 m
Slide 14: Dabo is uniquely positioned to expand Tx beyond procedures
Dabo is uniquely positioned to expand Tx beyond procedures ADJUVANT IVe Tx IN DEVELOPMENT ORAL DEVELOPMENT All five require multiple urethral violations with dwell times Only one: a targeted therapy Total instillations Total instillations ZUSDURI1 NDV-01 (Mitomycin hydrogel) (gemcitabine-docetaxel)
Slide 15: SURF302 was designed to select a dose for Phase 3
SURF302 was designed to select a dose for Phase 3 LG IR NMIBC, Marker Lesion Study Dabogratinib (TYRA-300) NCT06995677 Primary Endpoint Key Eligibility Criteria Cohort A CR at 3 mo CR at 3 months N=30 | 60mg QD Continue on Adults (≥18 years) study treatment FGFR3 activating gene alterations up to 24
Slide 16: 100% ORR at 60mg in single marker lesion patients
100% ORR at 60mg in single marker lesion patients PHASE 2 ABLATIVE TUMOR(S) REMAIN Evaluating Dabogratinib’s potential to shrink PHASE 3 ADJUVANT ALL TUMORS REMOVED Planned to evaluate Dabogratinib’s potential and ablate all lesions in bladder to prevent new lesion growth after tumor removal 60mg Si
Slide 17: IR NMIBC: SURF302 Data and Phase Dose Selection
IR NMIBC SURF302 Data and Phase 3 Dose Selection 17
Slide 18: SURF302 enrolled a highly recurrent, undertreated population
SURF302 enrolled a highly recurrent, undertreated population n=44 n=44 MEDIAN AGE Range (26-82) 70 (yrs) MEDIAN PRIOR: TURBT Range (0−10) 2 Intravesical (IVe) Tx3 Range (0−7) 0 n (%) n (%) 61% of patients had SEX AT BIRTH Male 31 (71) MARKER LESION 1 27 (61) no prior lines of NUMBER1 >1 16 (36) IVe
Slide 19: Favorable safety and tolerability data support chronic Tx potential
Favorable safety and tolerability data support chronic Tx potential TEAEs in Patients Treated with Dabogratinib, n (%) Adverse Events Were Manageable 60 mg (n=22) 50 mg (n=22) • No clinically significant hyperphosphatemia, Gr. 1 Gr. 2 Gr. 3 Gr. 1 Gr. 2 Gr. 3 nail toxicity or ocular toxicity Particip
Slide 20: GI events were limited and transient
GI events were limited and transient Diarrhea TEAEs in all safety evaluable patients (n=44) 50 mg Intermittent AE • No dose reductions or On Therapy interruptions from Grade 1 treatment-related diarrhea Grade 2 Ongoing AE • All cases were transient or intermittent 60 mg • One patient with history of
Slide 21: 60mg demonstrated robust clinical activity with a dose response
60mg demonstrated robust clinical activity with a dose response 60mg n=141 50mg n=121 3-mo BOR 3-mo & BOR FINDINGS ORR 79% (11) 79% (11) ORR 67% (8) • Clear dose response observed CR 57% (8) 64% (9) CR 33% (4) • Initial 60mg PR with a 6-mo assessment converted to a CR PR 21% (3) 14% (2) PR 33% (4) •
Slide 22: Evidence of response maintenance and maturation
Evidence of response maintenance and maturation Lesion Count Baseline Marker Lesion (Pre-resection) (Post Resection) 50 mg Complete Response (CR) Partial Response (PR) 60 mg Non CR Remains on study drug Discontinuation 1−8 No. of lesions pre/post resection August 31, 2026 cutoff, efficacy evaluable
Slide 23: Model projects likely plateauing of adjuvant efficacy above 60mg
Model projects likely plateauing of adjuvant efficacy above 60mg Predicted Steady State AUC by Dose (n=172) Response Rate by AUC across 50 and 60mg % Patients predicted >2500 AUCss 30,000 98% 86% 94% AUCss ng·hr/mL (Log10) ORR at >2500 AUCss 10,000 82% 58% AUCss ≤2500 n=12 >2500 n=14 3,000 21% AUCss
Slide 24: Clinical activity improved in patients with single marker lesion
Clinical activity improved in patients with single marker lesion Response Rate by ML across 50 and 60mg 60mg with 1 ML n=8 94% ORR with 1 ML Of the 7 non-responders across both doses all but one had multiple MLs; 3-mo BOR 1 ML n=16 ≥2 MLs n=10 of the 6 non-responders with ≥2MLs, only one had AUC ORR
Slide 25: Modeling supports our confidence in planned adjuvant Ph3
Modeling supports our confidence in planned adjuvant Ph3 Modeled DFS Curves4 DFS0 + (1-DFS0) x [(DoR x CR) + (DoR x PR)] = DFS24 λ = –ln(DFS₂₄) / 24 36%1 64%2 FGFR3-driven Efficacy 100 80 Dabo model 81% 60mg with 1 ML [(0.83 x 75%3) + (0.43 x 25%3)] = 81%2 0.2 DFS Probability (%) Scenarios 72% 60mg
Slide 26: IR NMIBC: Market Opportunity
IR NMIBC Market Opportunity 26
Slide 27: Our mission is to make dabogratinib the clear first-line choice
Our mission is to make dabogratinib the clear first-line choice LG IR NMIBC adjuvant patients1 Watch ~70% & Wait WIN ON EFFICACY AND CONVENIENCE POTENTIAL FOR A DAILY ORAL SWITCH CONSIDERATIONS Replace repeat catheterizations/instillations • Instrumentation fatigue IVe Tx ~30% • Potential for contin
Slide 28: Preference for oral Orgovyx transformed the ADT market
Preference for oral Orgovyx transformed the ADT market 1 Patient Preference2 COMPETE ON Community Urology Mode of admin. Patient Share1 CONVENIENCE Cardio. event risk 100% Testosterone surge after 92% initiation of ADT 0 10 20 30 80% RI estimates (%) Injectable ADT 60% 52% 2 Aligned Practice Economi
Slide 29: Our mission is to make dabogratinib the clear first-line choice
Our mission is to make dabogratinib the clear first-line choice LG IR NMIBC adjuvant patients1 EXPAND THE MARKET POTENTIAL FOR A DAILY ORAL Reduce recurrence and surgery Watch Reduce 3-month cystoscopy burden ~70% & Wait WIN ON EFFICACY AND CONVENIENCE POTENTIAL FOR A DAILY ORAL SWITCH CONSIDERATION
Slide 30: Research indicates patients would strongly value an oral therapy
Research indicates patients would strongly value an oral therapy LIFESTYLE APPEAL OF A DAILY ORAL PILL1 TREATMENT APPEAL1 How appealing is each of the following factors related to an oral pill that you take daily?* If oral treatment still required the same cystoscopy schedule for monitoring your rem
Slide 31: Urologists prioritize efficacy and relief from invasive procedures
Urologists prioritize efficacy and relief from invasive procedures UNMET NEEDS IN IR NMIBC1 Options 1. No unmet need at all To what extent, if at all, would you consider each of the 2. following an unmet need in the management of IR-NMIBC?* 3. 4. Moderate unmet need The majority of 5. Fewer repeat c
Slide 32: Our mission is to make dabogratinib the clear first-line choice
Our mission is to make dabogratinib the clear first-line choice LG IR NMIBC adjuvant patients1 EXPAND THE MARKET POTENTIAL FOR A DAILY ORAL TOTAL POTENTIAL MARKET SIZE2 >$5 Reduce recurrence and surgery Watch Reduce 3-month cystoscopy burden ~70% & Wait WIN ON EFFICACY BILLION AND CONVENIENCE POTENT
Slide 33: UTUC
UTUC 33
Slide 34: Dabogratinib could address specific unmet needs in LG UTUC
Dabogratinib could address specific unmet needs in LG UTUC LOW GRADE UTUC UNMET NEED Renal pelvis No high grade on biopsy or cytology ANATOMY Calyx Ureter length, orientation, ~85% ~3,000 and intra-renal anatomy presents challenges with UPPER TRACT FGFR3+ FGFR3+ seeking UROTHELIAL diagnosis and trea
Slide 35: Current kidney-sparing endoscopic surgery SoC has drawbacks
Current kidney-sparing endoscopic surgery SoC has drawbacks SIGNIFICANT RISKS POOR OUTCOMES MISSED TUMORS RECURRENCE AND PROGRESSION ≤25% missed due to ALL LG TUMORS challenging anatomy ~35–50% recur within 3 years and ~30% multifocality LG TUMORS >2cm 90.5% recur (median 4.9 mo) 31.7% progress (med
Slide 36: Jelmyto is more effective but comes with many limitations
Jelmyto, is more effective but comes with many limitations Efficacy Eligibility Administration 58% CR rate Renal pelvis (not ureters) 6 instillations: 56% 12-month DoR Tumors 5–15mm in size • Ureteral catheter with fluoroscopy or antegrade nephrostomy tube • Local anesthesia Safety 58% Ureteric obst
Slide 37: First LG UTUC patient has been dosed in Dabogratinib Ph2 Study
First LG UTUC patient has been dosed in Dabogratinib Ph2 Study LG UTUC, Marker Lesion Study Dabogratinib (TYRA-300) NCT07265947 Ph2a DOSE Primary Endpoint Key Eligibility Criteria FINDING CR within 6 months in Ph2b POTENTIAL FGFR3+ patients Adults (≥18 years) Cohort A PIVOTAL LR, LG UTUC based on AU
Slide 38: 60mg activity extends from IR NMIBC to first LG UTUC patient
60mg activity extends from IR NMIBC to first LG UTUC patient COMPLETE RESPONSE 73-year-old male, 60mg QD No dose interruptions or reductions Apr 2026 Aug 31 2026 Disease LG UTUC, Initial diagnosis date: History 2024 May Jun Jul Aug T2DM, BPH, CAD, cataracts, Marker Lesion Medical retinal pigment epi
Slide 39: ACHONDROPLASIA
ACHONDROPLASIA 39
Slide 40: Inhibiting FGFR3 may benefit people with skeletal dysplasia
Inhibiting FGFR3 may benefit people with skeletal dysplasia FGFR3 6 5 ACH HCH Over-activation of this ~5’9” ~5’4” protein in bone growth 4 1.76m1 1.63m1 plates underlies both ~4’7” ACH and HCH 3 ~4’3” 1.39m3 1.30m2 2 1 1. CDC Vital and Health Statistics (represents average US male and female heights
Slide 41: ACH can result in serious clinical complications
ACH can result in serious clinical complications MECHANISM COMPLICATIONS ACH is the most FGFR3 G380R gain of function Infants can face serious common cause of mutation drives ~99% of complications related to critical disproportionate ACH1,2 foramen magnum stenosis1,3 short stature FGFR3 inhibits cho
Slide 42: ~6cm AHV is potentially leaving efficacy on the table
~6cm AHV is potentially leaving efficacy on the table Infigratinib ~2.7cm/yr avg AHV improvement Average ACH 6.05 Pediatric would be needed over 17 years to 1.7cm>placebo AHV ~4.04 7.66 reach final average male stature11 46cm (18”) 26 cm (10”)3 ~5’9” cm/year 3 4 5 6 7 8 9 1.76m1 Per BioMarin ACH (FG
Slide 43: FGFR3 inhibition has been shown to accelerate height velocity
FGFR3 inhibition has been shown to accelerate height velocity Pan-FGFR Infigratinib for Pediatric Oncology Average ACH (1/6 oncology dose) Pediatric (oncology dose causing fractures) AHV ~4.04 6.05 7.66 19.29 HEIGHT PERCENTILES Oncology patients with physiologic growth plate signaling treated with P
Slide 44: Evidence points to FGFR3 inhibition potential beyond ACH
Evidence points to FGFR3 inhibition potential beyond ACH GENETIC PRECLINICAL CLINICAL FGFR3 mutation phenotypes point to a FGFR3 inhibition below an IC90 drove Oncology doses of pan-FGFR drive key role in regulating bone growth. hyper-typical growth in WT mice.4 hyper-typical growth in pediatric can
Slide 45: Safety sentinel cohort expanded with DL5 in Ph2 BEACH301
Safety sentinel cohort expanded with DL5 in Ph2 BEACH301 Cohorts 1 and 2* months on treatment N=* DOSE (mg/kg) Natural Hx (6 mo) 0 6 12 Sentinel Safety Cohort 6 0.625 ACH age 5-10 No run-in 6 0.50 Anticipate n=~25 total enrollment 6 0.375 DOSE (mg/kg) 0.625 6 0.25 0.50 6 0.125 0.375 0.25 *Co
Slide 46: There are many development opportunities beyond ACH and HCH
There are many development opportunities beyond ACH and HCH FGFR3 GERMLINE OTHER GENETIC PEDIATRIC SHORT MUTATIONS SHORT STATURE STATURE SKELETAL DYSPLASIA Leri-Weill dyschondrosteosis (~26K) Genetic and Idiopathic short ODD & RPD Turner syndrome (~10K) stature (~700K1) Achondroplasia (~3K) granted
Slide 47: Gearing up for potential pivotal trials in 3 blockbuster indications
Gearing up for potential pivotal trials in 3 blockbuster indications Validated NASDAQ: FGFR3 alterations drive conditions with high unmet needs Target TYRA CASH: The first oral, once-daily, highly selective FGFR3 inhibitor Differentiated $727M (Pro-forma 2Q26)* 60mg PoC Molecule IR NMIBC All MLs: 79
Tyra Biosciences — Investor Presentation (September 2026) on 6ix